Recombinant humanized anti-VEGF monoclonal antibody (Stainwei)

重组人源化抗血管内皮生长因子(VEGF)单抗（思坦维）

Report date: 2024/12/11 20:00:45

Base Information

Drug NameRecombinant humanized anti-VEGF monoclonal antibody (Stainwei)
Drug Alias NameSylvanism BiopharmhPV19单克隆抗体眼用注射液hPV19 ophthalmic injection人源化hPV19单克隆抗体苏洛晍眼用注射液 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsSolid tumoursWet age-related macular degenerationMacular Edema +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesSuzhou Stainwei Biotech IncAcroImmune Group
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou Stainwei Biotech Inc
Inactive CompaniesN/A
Active IndicationsMacular EdemaMacular Degeneration
Inactive IndicationsSolid tumoursWet age-related macular degeneration

Other Information

ATC CodeN/A
Related LinksN/A